News & Events

Corporate Presentation

Download April 2026 Presentation

Select Highlights

January 12, 2026

Latest Press Releases

May 4, 2026

Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting

March 16, 2026

Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments

January 12, 2026

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

January 12, 2026

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

More Press Releases

Events and Presentations

January 15, 2026 at 9:30 a.m. PT

J.P. Morgan Healthcare Conference

Conference Website »

November 11, 2025 at 11:20 a.m. ET

Stifel 2025 Healthcare Conference

November 10, 2025 at 1:30 p.m. ET

Guggenheim Second Annual Healthcare Innovation Conference

September 16, 2025 3:00 p.m. ET

Stifel 2025 Virtual Immunology and Inflammation Forum

Access Webcast »

News Coverage Highlights

August 7, 2023

BioCentury: Recludix: targeting STATs via their SH2 domains

July 20, 2023

BioWorld: Recludix enters a potential $1.2B deal with Sanofi

July 20, 2023

SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix

July 20, 2023

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

July 20, 2023

Corporate Presentation

Select Highlights

News: Financing from Institutional Investors & Lilly

News: REX-8756 Phase 1 Milestone

SID Conference: BTK Data

Latest Press Releases

Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting

Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

Events and Presentations

J.P. Morgan Healthcare Conference

Stifel 2025 Healthcare Conference

Guggenheim Second Annual Healthcare Innovation Conference

Stifel 2025 Virtual Immunology and Inflammation Forum

News Coverage Highlights

BioCentury: Recludix: targeting STATs via their SH2 domains

BioWorld: Recludix enters a potential $1.2B deal with Sanofi

SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with Recludix